Moleculin Biotech to Announce Q1 2025 Financial Results

Moleculin Biotech ( (MBRX) ) has provided an announcement.

On May 7, 2025, Moleculin Biotech announced its plan to report financial results for the first quarter of 2025 on May 13, 2025, followed by a conference call and webcast on May 14, 2025. This announcement highlights Moleculin’s ongoing efforts in advancing its drug candidates, particularly Annamycin, which is in a pivotal Phase 3 trial for AML. The company’s progress in drug development could significantly impact its market positioning and stakeholder interests.

Spark’s Take on MBRX Stock

According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.

Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.

To see Spark’s full report on MBRX stock, click here.

More about Moleculin Biotech

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focusing on developing therapeutic candidates for hard-to-treat tumors and viruses. Its lead program, Annamycin, is designed to treat relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases, aiming to overcome multidrug resistance and cardiotoxicity issues associated with current treatments. The company is also developing WP1066, targeting brain tumors and pancreatic cancer, and WP1122 for pathogenic viruses and certain cancers.

Average Trading Volume: 5,868,660

Technical Sentiment Signal: Sell

Current Market Cap: $14.41M

Learn more about MBRX stock on TipRanks’ Stock Analysis page.